Cybin to Participate at the 27th Annual Milken Institute Global Conference
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
Cybin Initiates Phase 2 Study of CYB004 in Generalized Anxiety Disorder
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003
Cybin Receives Breakthrough Therapy Designation for Psychedelic Molecule CYB003
Cybin to Present at the TD Cowen 44th Annual Health Care Conference